Drugs / OTX-TKI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03630315 | Feb 2019 → Jan 2024 | wet macular degeneration | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04989699 Comparator | Jul 2021 → Feb 2023 | wet macular degeneration | Ocular Therapeutix, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OTX-TKI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03630315 ↗ |
| Modality | Small molecule | “a small molecule tyrosine kinase inhibitor (TKI)” NCT03630315 ↗ |
| Route | Intravitreal | “for Intravitreal Use” NCT03630315 ↗ |